Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics
| Autor: | Tanja Dominko, Pamela J. Weathers, David Dolivo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
BUN
blood urea nitrogen Artesunate Review Pharmacology Col I type I collagen LAP latency-associated peptide chemistry.chemical_compound 0302 clinical medicine Scar HUVEC human umbilical vein endothelial cell Fibrosis CCl4 carbon tetrachloride NAG N-acetyl-β-d-glucosaminidase General Pharmacology Toxicology and Pharmaceutics Artemisinin HA hyaluronic acid 0303 health sciences LDH lactate dehydrogenase LDH - Lactate dehydrogenase mTOR mechanistic target of rapamycin TGF β-transforming growth factor-β DLA dried leaf Artemisia i.p. intraperitoneal HSC hepatic stellate cell ALP - Alkaline phosphatase DHA dihydroartemisinin ECM extracellular matrix MMP matrix metalloproteinase Alt alanine aminotransferase 030220 oncology & carcinogenesis MI myocardial infarction Fibroblast TIMP tissue inhibitor of metalloproteinase medicine.drug TGF-β Anti fibrotic ASP aspartate aminotransferase PCNA proliferating cell nuclear antigen BDL bile duct ligation FLS fibroblast-like synoviocyte STZ streptozotocin PHN passive heymann nephritis CTGF connective tissue growth factor 03 medical and health sciences ROS reactive oxygen species ALT alanine aminotransferase parasitic diseases medicine BAD BCL-2-associated agonist of cell death sCr serum creatinine NICD Notch intracellular domain UUO unilateral ureteral obstruction 030304 developmental biology Myofibroblast ALP alkaline phosphatase business.industry lcsh:RM1-950 medicine.disease AMPK AMP-activated protein kinase lcsh:Therapeutics. Pharmacology Artemisia chemistry Tissue fibrosis BSA bovine serum albumin α-SMA smooth muscle α-actin business EMT epithelial-to-mesenchymal transition MAPK mitogen-activated protein kinase |
| Zdroj: | Acta Pharmaceutica Sinica B, Vol 11, Iss 2, Pp 322-339 (2021) Acta Pharmaceutica Sinica. B |
| ISSN: | 2211-3835 |
| DOI: | 10.1016/j.apsb.2020.09.001 |
| Popis: | Fibrosis is a pathological reparative process that can occur in most organs and is responsible for nearly half of deaths in the developed world. Despite considerable research, few therapies have proven effective and been approved clinically for treatment of fibrosis. Artemisinin compounds are best known as antimalarial therapeutics, but they also demonstrate antiparasitic, antibacterial, anticancer, and anti-fibrotic effects. Here we summarize literature describing anti-fibrotic effects of artemisinin compounds in in vivo and in vitro models of tissue fibrosis, and we describe the likely mechanisms by which artemisinin compounds appear to inhibit cellular and tissue processes that lead to fibrosis. To consider alternative routes of administration of artemisinin for treatment of internal organ fibrosis, we also discuss the potential for more direct oral delivery of Artemisia plant material to enhance bioavailability and efficacy of artemisinin compared to administration of purified artemisinin drugs at comparable doses. It is our hope that greater understanding of the broad anti-fibrotic effects of artemisinin drugs will enable and promote their use as therapeutics for treatment of fibrotic diseases. Graphical abstract Artemisinin drugs, isolated from Artemisia, effectively prevent or treat multiple types of tissue fibrosis when administered to several preclinical animal models of varied etiologies.Image 1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|